Correspondence 0001213900-22-073148 from REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC.
Date: Nov. 16, 2022 · CIK: 0001810560 · Accession: 0001213900-22-073148
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268076
Referenced dates: November 14, 2022
Letter
J.P. GALDA & CO.
Attorneys-at-Law
40 Montgomery Avenue, LTW 220
Ardmore, Pennsylvania 19003
Telephone (215) 815-1534
November 16, 2022
Via Email and EDGAR
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attention: Daniel Crawford
Joe McCann
Re: Revelation Biosciences, Inc.
Registration Statement on Form S-1
Commission File No. 333-268076
Gentlemen:
We are in receipt of the Staff’s comment letter dated November 14, 2022 (the “Comment Letter”) relating to the above-captioned Registration Statement (the “Registration Statement”).
The numbered paragraphs below refer to the numbered comments in the Comment Letter.
1. We have amended the cover page of the prospectus to disclose the termination date of the offering.
2. The shares, Class C Common Stock Warrants and pre-funded warrants will be delivered on the date that is two trading days after we enter into securities purchase agreements to sell the securities offered pursuant to the registration statement.
3. The form of placement agency agreement is filed as an exhibit.
We have also amended the Registration statement to update the financial statements. With this amendment we would like to go effective as soon as possible to address the NASDAQ compliance issue I discussed with Mr. Crawford. I will be calling him shortly after this filing.
Very truly yours,
/s/ Joseph P. Galda
Show Raw Text
CORRESP
1
filename1.htm
J.P.
GALDA & CO.
Attorneys-at-Law
40 Montgomery
Avenue, LTW 220
Ardmore,
Pennsylvania 19003
Telephone
(215) 815-1534
November 16, 2022
Via Email and EDGAR
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attention: Daniel Crawford
Joe McCann
Re: Revelation Biosciences, Inc.
Registration Statement on Form S-1
Commission File No. 333-268076
Gentlemen:
We are in receipt of the Staff’s comment letter
dated November 14, 2022 (the “Comment Letter”) relating to the above-captioned Registration Statement (the “Registration
Statement”).
The numbered paragraphs below refer to the numbered
comments in the Comment Letter.
1. We have amended the cover page of the prospectus to disclose
the termination date of the offering.
2. The shares, Class C Common Stock Warrants and pre-funded warrants will be delivered on the date that is two trading days after we enter
into securities purchase agreements to sell the securities offered pursuant to the registration statement.
3. The form of placement agency agreement is filed as an exhibit.
We have also amended the Registration statement
to update the financial statements. With this amendment we would like to go effective as soon as possible to address the NASDAQ compliance
issue I discussed with Mr. Crawford. I will be calling him shortly after this filing.
Very truly yours,
/s/ Joseph P. Galda